Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports Article Swipe
Uma Mahadevan
,
Gweneth Levy
,
Lianne S. Gensler
,
Mira Ali
,
Ana P. Lacerda
,
Lani R. Wegrzyn
,
Hannah Palac
,
Tina Bhutani-Jacques
,
Millie D. Long
,
Megan E. B. Clowse
,
Alexa B. Kimball
,
Christina Chambers
,
Anthony R. Scialli
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1007/s40264-024-01454-0
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1007/s40264-024-01454-0
As the data are limited for in utero exposure to upadacitinib, definitive conclusions cannot be drawn regarding the effect of upadacitinib on pregnancy outcomes. Rates of adverse pregnancy outcomes with upadacitinib exposure were comparable to rates observed in the general population or patients with autoimmune inflammatory diseases. To date, no apparent evidence of teratogenicity exists in the analyses of human pregnancies exposed to upadacitinib during the first trimester.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1007/s40264-024-01454-0
- https://link.springer.com/content/pdf/10.1007/s40264-024-01454-0.pdf
- OA Status
- hybrid
- Cited By
- 22
- References
- 21
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4400662839
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4400662839Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1007/s40264-024-01454-0Digital Object Identifier
- Title
-
Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing ReportsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-07-15Full publication date if available
- Authors
-
Uma Mahadevan, Gweneth Levy, Lianne S. Gensler, Mira Ali, Ana P. Lacerda, Lani R. Wegrzyn, Hannah Palac, Tina Bhutani-Jacques, Millie D. Long, Megan E. B. Clowse, Alexa B. Kimball, Christina Chambers, Anthony R. ScialliList of authors in order
- Landing page
-
https://doi.org/10.1007/s40264-024-01454-0Publisher landing page
- PDF URL
-
https://link.springer.com/content/pdf/10.1007/s40264-024-01454-0.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://link.springer.com/content/pdf/10.1007/s40264-024-01454-0.pdfDirect OA link when available
- Concepts
-
Medicine, Postmarketing surveillance, Pregnancy, Clinical trial, Pharmacoepidemiology, Pharmacology, Adverse effect, Internal medicine, Medical prescription, Biology, GeneticsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
22Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 19, 2024: 3Per-year citation counts (last 5 years)
- References (count)
-
21Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4400662839 |
|---|---|
| doi | https://doi.org/10.1007/s40264-024-01454-0 |
| ids.doi | https://doi.org/10.1007/s40264-024-01454-0 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39008024 |
| ids.openalex | https://openalex.org/W4400662839 |
| fwci | 29.60685488 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D011247 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Pregnancy |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D005260 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Female |
| mesh[3].qualifier_ui | Q000453 |
| mesh[3].descriptor_ui | D011256 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | epidemiology |
| mesh[3].descriptor_name | Pregnancy Outcome |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D000328 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Adult |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D011358 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Product Surveillance, Postmarketing |
| mesh[6].qualifier_ui | Q000009 |
| mesh[6].descriptor_ui | D006575 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | adverse effects |
| mesh[6].descriptor_name | Heterocyclic Compounds, 3-Ring |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D006575 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Heterocyclic Compounds, 3-Ring |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D002986 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Clinical Trials as Topic |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D012189 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Retrospective Studies |
| mesh[10].qualifier_ui | Q000188 |
| mesh[10].descriptor_ui | D011248 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | drug therapy |
| mesh[10].descriptor_name | Pregnancy Complications |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D055815 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Young Adult |
| mesh[12].qualifier_ui | Q000453 |
| mesh[12].descriptor_ui | D000014 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | epidemiology |
| mesh[12].descriptor_name | Abnormalities, Drug-Induced |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D006801 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Humans |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D011247 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Pregnancy |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D005260 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Female |
| mesh[16].qualifier_ui | Q000453 |
| mesh[16].descriptor_ui | D011256 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | epidemiology |
| mesh[16].descriptor_name | Pregnancy Outcome |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000328 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Adult |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D011358 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Product Surveillance, Postmarketing |
| mesh[19].qualifier_ui | Q000009 |
| mesh[19].descriptor_ui | D006575 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | adverse effects |
| mesh[19].descriptor_name | Heterocyclic Compounds, 3-Ring |
| mesh[20].qualifier_ui | Q000627 |
| mesh[20].descriptor_ui | D006575 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | therapeutic use |
| mesh[20].descriptor_name | Heterocyclic Compounds, 3-Ring |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D002986 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Clinical Trials as Topic |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D012189 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Retrospective Studies |
| mesh[23].qualifier_ui | Q000188 |
| mesh[23].descriptor_ui | D011248 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | drug therapy |
| mesh[23].descriptor_name | Pregnancy Complications |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D055815 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Young Adult |
| mesh[25].qualifier_ui | Q000453 |
| mesh[25].descriptor_ui | D000014 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | epidemiology |
| mesh[25].descriptor_name | Abnormalities, Drug-Induced |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D006801 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Humans |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D011247 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Pregnancy |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D005260 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Female |
| mesh[29].qualifier_ui | Q000453 |
| mesh[29].descriptor_ui | D011256 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | epidemiology |
| mesh[29].descriptor_name | Pregnancy Outcome |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D000328 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Adult |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D011358 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Product Surveillance, Postmarketing |
| mesh[32].qualifier_ui | Q000009 |
| mesh[32].descriptor_ui | D006575 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | adverse effects |
| mesh[32].descriptor_name | Heterocyclic Compounds, 3-Ring |
| mesh[33].qualifier_ui | Q000627 |
| mesh[33].descriptor_ui | D006575 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | therapeutic use |
| mesh[33].descriptor_name | Heterocyclic Compounds, 3-Ring |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D002986 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Clinical Trials as Topic |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D012189 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Retrospective Studies |
| mesh[36].qualifier_ui | Q000188 |
| mesh[36].descriptor_ui | D011248 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | drug therapy |
| mesh[36].descriptor_name | Pregnancy Complications |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D055815 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Young Adult |
| mesh[38].qualifier_ui | Q000453 |
| mesh[38].descriptor_ui | D000014 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | epidemiology |
| mesh[38].descriptor_name | Abnormalities, Drug-Induced |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D006801 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Humans |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D011247 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Pregnancy |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D005260 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Female |
| mesh[42].qualifier_ui | Q000453 |
| mesh[42].descriptor_ui | D011256 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | epidemiology |
| mesh[42].descriptor_name | Pregnancy Outcome |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D000328 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Adult |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D011358 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Product Surveillance, Postmarketing |
| mesh[45].qualifier_ui | Q000009 |
| mesh[45].descriptor_ui | D006575 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | adverse effects |
| mesh[45].descriptor_name | Heterocyclic Compounds, 3-Ring |
| mesh[46].qualifier_ui | Q000627 |
| mesh[46].descriptor_ui | D006575 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | therapeutic use |
| mesh[46].descriptor_name | Heterocyclic Compounds, 3-Ring |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D002986 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Clinical Trials as Topic |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D012189 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Retrospective Studies |
| mesh[49].qualifier_ui | Q000188 |
| mesh[49].descriptor_ui | D011248 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | drug therapy |
| mesh[49].descriptor_name | Pregnancy Complications |
| type | article |
| title | Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports |
| biblio.issue | 10 |
| biblio.volume | 47 |
| biblio.last_page | 1049 |
| biblio.first_page | 1039 |
| grants[0].funder | https://openalex.org/F4320309117 |
| grants[0].award_id | |
| grants[0].funder_display_name | AbbVie |
| topics[0].id | https://openalex.org/T11964 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9995999932289124 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2739 |
| topics[0].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[0].display_name | Pregnancy and Medication Impact |
| topics[1].id | https://openalex.org/T10935 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9932000041007996 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2743 |
| topics[1].subfield.display_name | Reproductive Medicine |
| topics[1].display_name | Endometriosis Research and Treatment |
| topics[2].id | https://openalex.org/T10290 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9871000051498413 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2729 |
| topics[2].subfield.display_name | Obstetrics and Gynecology |
| topics[2].display_name | Pregnancy and preeclampsia studies |
| funders[0].id | https://openalex.org/F4320309117 |
| funders[0].ror | https://ror.org/02g5p4n58 |
| funders[0].display_name | AbbVie |
| is_xpac | False |
| apc_list.value | 3390 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4390 |
| apc_paid.value | 3390 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 4390 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9660522937774658 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C197636746 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6691826581954956 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7234359 |
| concepts[1].display_name | Postmarketing surveillance |
| concepts[2].id | https://openalex.org/C2779234561 |
| concepts[2].level | 2 |
| concepts[2].score | 0.539574146270752 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11995 |
| concepts[2].display_name | Pregnancy |
| concepts[3].id | https://openalex.org/C535046627 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5152249932289124 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[3].display_name | Clinical trial |
| concepts[4].id | https://openalex.org/C23276603 |
| concepts[4].level | 3 |
| concepts[4].score | 0.4309547245502472 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q158230 |
| concepts[4].display_name | Pharmacoepidemiology |
| concepts[5].id | https://openalex.org/C98274493 |
| concepts[5].level | 1 |
| concepts[5].score | 0.4021316170692444 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[5].display_name | Pharmacology |
| concepts[6].id | https://openalex.org/C197934379 |
| concepts[6].level | 2 |
| concepts[6].score | 0.34919002652168274 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[6].display_name | Adverse effect |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.27461063861846924 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C2426938 |
| concepts[8].level | 2 |
| concepts[8].score | 0.09672176837921143 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q3355478 |
| concepts[8].display_name | Medical prescription |
| concepts[9].id | https://openalex.org/C86803240 |
| concepts[9].level | 0 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[9].display_name | Biology |
| concepts[10].id | https://openalex.org/C54355233 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[10].display_name | Genetics |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9660522937774658 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/postmarketing-surveillance |
| keywords[1].score | 0.6691826581954956 |
| keywords[1].display_name | Postmarketing surveillance |
| keywords[2].id | https://openalex.org/keywords/pregnancy |
| keywords[2].score | 0.539574146270752 |
| keywords[2].display_name | Pregnancy |
| keywords[3].id | https://openalex.org/keywords/clinical-trial |
| keywords[3].score | 0.5152249932289124 |
| keywords[3].display_name | Clinical trial |
| keywords[4].id | https://openalex.org/keywords/pharmacoepidemiology |
| keywords[4].score | 0.4309547245502472 |
| keywords[4].display_name | Pharmacoepidemiology |
| keywords[5].id | https://openalex.org/keywords/pharmacology |
| keywords[5].score | 0.4021316170692444 |
| keywords[5].display_name | Pharmacology |
| keywords[6].id | https://openalex.org/keywords/adverse-effect |
| keywords[6].score | 0.34919002652168274 |
| keywords[6].display_name | Adverse effect |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.27461063861846924 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/medical-prescription |
| keywords[8].score | 0.09672176837921143 |
| keywords[8].display_name | Medical prescription |
| language | en |
| locations[0].id | doi:10.1007/s40264-024-01454-0 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S49488433 |
| locations[0].source.issn | 0114-5916, 1179-1942 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0114-5916 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Drug Safety |
| locations[0].source.host_organization | https://openalex.org/P4310320330 |
| locations[0].source.host_organization_name | Adis, Springer Healthcare |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320330 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | https://link.springer.com/content/pdf/10.1007/s40264-024-01454-0.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Drug Safety |
| locations[0].landing_page_url | https://doi.org/10.1007/s40264-024-01454-0 |
| locations[1].id | pmid:39008024 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Drug safety |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39008024 |
| locations[2].id | pmh:oai:escholarship.org:ark:/13030/qt61g6m445 |
| locations[2].is_oa | True |
| locations[2].source | |
| locations[2].license | cc-by-nc |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Drug Safety: The Official Journal of the International Society of Pharmacovigilance, vol 47, iss 10 |
| locations[2].landing_page_url | https://escholarship.org/uc/item/61g6m445 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:11399166 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Drug Saf |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11399166 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5101527594 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3067-8061 |
| authorships[0].author.display_name | Uma Mahadevan |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[0].affiliations[0].raw_affiliation_string | Division of Gastroenterology and Hepatology, University of California San Francisco, 1701 Divisadero Street #120, San Francisco, CA, 94010, USA |
| authorships[0].institutions[0].id | https://openalex.org/I180670191 |
| authorships[0].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | University of California, San Francisco |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Uma Mahadevan |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Division of Gastroenterology and Hepatology, University of California San Francisco, 1701 Divisadero Street #120, San Francisco, CA, 94010, USA |
| authorships[1].author.id | https://openalex.org/A5006579778 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Gweneth Levy |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2948539688 |
| authorships[1].affiliations[0].raw_affiliation_string | AbbVie, Inc., Chicago, IL, USA |
| authorships[1].institutions[0].id | https://openalex.org/I2948539688 |
| authorships[1].institutions[0].ror | https://ror.org/02g5p4n58 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I2948539688 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | AbbVie (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Gweneth Levy |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | AbbVie, Inc., Chicago, IL, USA |
| authorships[2].author.id | https://openalex.org/A5034952463 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-6314-5336 |
| authorships[2].author.display_name | Lianne S. Gensler |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[2].affiliations[0].raw_affiliation_string | Division of Rheumatology, University of California San Francisco, San Francisco, CA, USA |
| authorships[2].institutions[0].id | https://openalex.org/I180670191 |
| authorships[2].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | University of California, San Francisco |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Lianne Gensler |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Division of Rheumatology, University of California San Francisco, San Francisco, CA, USA |
| authorships[3].author.id | https://openalex.org/A5019108918 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Mira Ali |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2948539688 |
| authorships[3].affiliations[0].raw_affiliation_string | AbbVie, Inc., Chicago, IL, USA |
| authorships[3].institutions[0].id | https://openalex.org/I2948539688 |
| authorships[3].institutions[0].ror | https://ror.org/02g5p4n58 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I2948539688 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | AbbVie (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mira Ali |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | AbbVie, Inc., Chicago, IL, USA |
| authorships[4].author.id | https://openalex.org/A5088717074 |
| authorships[4].author.orcid | https://orcid.org/0009-0009-6291-9171 |
| authorships[4].author.display_name | Ana P. Lacerda |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2948539688 |
| authorships[4].affiliations[0].raw_affiliation_string | AbbVie, Inc., Chicago, IL, USA |
| authorships[4].institutions[0].id | https://openalex.org/I2948539688 |
| authorships[4].institutions[0].ror | https://ror.org/02g5p4n58 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I2948539688 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | AbbVie (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Ana P. Lacerda |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | AbbVie, Inc., Chicago, IL, USA |
| authorships[5].author.id | https://openalex.org/A5040858815 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Lani R. Wegrzyn |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I2948539688 |
| authorships[5].affiliations[0].raw_affiliation_string | AbbVie, Inc., Chicago, IL, USA |
| authorships[5].institutions[0].id | https://openalex.org/I2948539688 |
| authorships[5].institutions[0].ror | https://ror.org/02g5p4n58 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I2948539688 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | AbbVie (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Lani Wegrzyn |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | AbbVie, Inc., Chicago, IL, USA |
| authorships[6].author.id | https://openalex.org/A5048819265 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-1314-3329 |
| authorships[6].author.display_name | Hannah Palac |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I2948539688 |
| authorships[6].affiliations[0].raw_affiliation_string | AbbVie, Inc., Chicago, IL, USA |
| authorships[6].institutions[0].id | https://openalex.org/I2948539688 |
| authorships[6].institutions[0].ror | https://ror.org/02g5p4n58 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I2948539688 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | AbbVie (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Hannah Palac |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | AbbVie, Inc., Chicago, IL, USA |
| authorships[7].author.id | https://openalex.org/A5104544932 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Tina Bhutani-Jacques |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[7].affiliations[0].raw_affiliation_string | Division of Rheumatology, University of California San Francisco, San Francisco, CA, USA |
| authorships[7].institutions[0].id | https://openalex.org/I180670191 |
| authorships[7].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | University of California, San Francisco |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Tina Bhutani-Jacques |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Division of Rheumatology, University of California San Francisco, San Francisco, CA, USA |
| authorships[8].author.id | https://openalex.org/A5071230912 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-5983-2758 |
| authorships[8].author.display_name | Millie D. Long |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I114027177 |
| authorships[8].affiliations[0].raw_affiliation_string | University of North Carolina at Chapel Hill, Chapel Hill, NC, USA |
| authorships[8].institutions[0].id | https://openalex.org/I114027177 |
| authorships[8].institutions[0].ror | https://ror.org/0130frc33 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I114027177 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | University of North Carolina at Chapel Hill |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Millie Long |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | University of North Carolina at Chapel Hill, Chapel Hill, NC, USA |
| authorships[9].author.id | https://openalex.org/A5085160815 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-8579-3470 |
| authorships[9].author.display_name | Megan E. B. Clowse |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I170897317 |
| authorships[9].affiliations[0].raw_affiliation_string | Division of Rheumatology and Immunology, Duke University, Durham, NC, USA |
| authorships[9].institutions[0].id | https://openalex.org/I170897317 |
| authorships[9].institutions[0].ror | https://ror.org/00py81415 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I170897317 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Duke University |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Megan E. B. Clowse |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Division of Rheumatology and Immunology, Duke University, Durham, NC, USA |
| authorships[10].author.id | https://openalex.org/A5059337854 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-9405-0479 |
| authorships[10].author.display_name | Alexa B. Kimball |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I1316535847, https://openalex.org/I136199984 |
| authorships[10].affiliations[0].raw_affiliation_string | Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA |
| authorships[10].institutions[0].id | https://openalex.org/I1316535847 |
| authorships[10].institutions[0].ror | https://ror.org/04drvxt59 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I1316535847 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Beth Israel Deaconess Medical Center |
| authorships[10].institutions[1].id | https://openalex.org/I136199984 |
| authorships[10].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[10].institutions[1].type | education |
| authorships[10].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[10].institutions[1].country_code | US |
| authorships[10].institutions[1].display_name | Harvard University |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Alexa B. Kimball |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA |
| authorships[11].author.id | https://openalex.org/A5007438752 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4675-7722 |
| authorships[11].author.display_name | Christina Chambers |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I36258959 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA |
| authorships[11].institutions[0].id | https://openalex.org/I36258959 |
| authorships[11].institutions[0].ror | https://ror.org/0168r3w48 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I36258959 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | University of California, San Diego |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Christina Chambers |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA |
| authorships[12].author.id | https://openalex.org/A5029493372 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-1351-4572 |
| authorships[12].author.display_name | Anthony R. Scialli |
| authorships[12].affiliations[0].raw_affiliation_string | Scialli Consulting LLC, Washington, DC, USA |
| authorships[12].author_position | last |
| authorships[12].raw_author_name | Anthony R. Scialli |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Scialli Consulting LLC, Washington, DC, USA |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://link.springer.com/content/pdf/10.1007/s40264-024-01454-0.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11964 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9995999932289124 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2739 |
| primary_topic.subfield.display_name | Public Health, Environmental and Occupational Health |
| primary_topic.display_name | Pregnancy and Medication Impact |
| related_works | https://openalex.org/W2204990270, https://openalex.org/W1979198508, https://openalex.org/W2485573117, https://openalex.org/W2403648853, https://openalex.org/W132857552, https://openalex.org/W2072379699, https://openalex.org/W1985435777, https://openalex.org/W2486045595, https://openalex.org/W2215269061, https://openalex.org/W4248725768 |
| cited_by_count | 22 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 19 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1007/s40264-024-01454-0 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S49488433 |
| best_oa_location.source.issn | 0114-5916, 1179-1942 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0114-5916 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Drug Safety |
| best_oa_location.source.host_organization | https://openalex.org/P4310320330 |
| best_oa_location.source.host_organization_name | Adis, Springer Healthcare |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320330 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s40264-024-01454-0.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Drug Safety |
| best_oa_location.landing_page_url | https://doi.org/10.1007/s40264-024-01454-0 |
| primary_location.id | doi:10.1007/s40264-024-01454-0 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S49488433 |
| primary_location.source.issn | 0114-5916, 1179-1942 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0114-5916 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Drug Safety |
| primary_location.source.host_organization | https://openalex.org/P4310320330 |
| primary_location.source.host_organization_name | Adis, Springer Healthcare |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320330 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s40264-024-01454-0.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Drug Safety |
| primary_location.landing_page_url | https://doi.org/10.1007/s40264-024-01454-0 |
| publication_date | 2024-07-15 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W3004601288, https://openalex.org/W3035163569, https://openalex.org/W4388863091, https://openalex.org/W2067708751, https://openalex.org/W1950578521, https://openalex.org/W3153443216, https://openalex.org/W2903690758, https://openalex.org/W2929672222, https://openalex.org/W4224295452, https://openalex.org/W2417133546, https://openalex.org/W3162368831, https://openalex.org/W2809935712, https://openalex.org/W2977585436, https://openalex.org/W2261130877, https://openalex.org/W1495532091, https://openalex.org/W1952948259, https://openalex.org/W3014453514, https://openalex.org/W4211227556, https://openalex.org/W2764285415, https://openalex.org/W2111612101, https://openalex.org/W1962974240 |
| referenced_works_count | 21 |
| abstract_inverted_index.As | 0 |
| abstract_inverted_index.To | 47 |
| abstract_inverted_index.be | 14 |
| abstract_inverted_index.in | 6, 37, 55 |
| abstract_inverted_index.no | 49 |
| abstract_inverted_index.of | 19, 25, 52, 58 |
| abstract_inverted_index.on | 21 |
| abstract_inverted_index.or | 41 |
| abstract_inverted_index.to | 9, 34, 62 |
| abstract_inverted_index.are | 3 |
| abstract_inverted_index.for | 5 |
| abstract_inverted_index.the | 1, 17, 38, 56, 65 |
| abstract_inverted_index.data | 2 |
| abstract_inverted_index.were | 32 |
| abstract_inverted_index.with | 29, 43 |
| abstract_inverted_index.Rates | 24 |
| abstract_inverted_index.date, | 48 |
| abstract_inverted_index.drawn | 15 |
| abstract_inverted_index.first | 66 |
| abstract_inverted_index.human | 59 |
| abstract_inverted_index.rates | 35 |
| abstract_inverted_index.utero | 7 |
| abstract_inverted_index.cannot | 13 |
| abstract_inverted_index.during | 64 |
| abstract_inverted_index.effect | 18 |
| abstract_inverted_index.exists | 54 |
| abstract_inverted_index.adverse | 26 |
| abstract_inverted_index.exposed | 61 |
| abstract_inverted_index.general | 39 |
| abstract_inverted_index.limited | 4 |
| abstract_inverted_index.analyses | 57 |
| abstract_inverted_index.apparent | 50 |
| abstract_inverted_index.evidence | 51 |
| abstract_inverted_index.exposure | 8, 31 |
| abstract_inverted_index.observed | 36 |
| abstract_inverted_index.outcomes | 28 |
| abstract_inverted_index.patients | 42 |
| abstract_inverted_index.diseases. | 46 |
| abstract_inverted_index.outcomes. | 23 |
| abstract_inverted_index.pregnancy | 22, 27 |
| abstract_inverted_index.regarding | 16 |
| abstract_inverted_index.autoimmune | 44 |
| abstract_inverted_index.comparable | 33 |
| abstract_inverted_index.definitive | 11 |
| abstract_inverted_index.population | 40 |
| abstract_inverted_index.trimester. | 67 |
| abstract_inverted_index.conclusions | 12 |
| abstract_inverted_index.pregnancies | 60 |
| abstract_inverted_index.inflammatory | 45 |
| abstract_inverted_index.upadacitinib | 20, 30, 63 |
| abstract_inverted_index.upadacitinib, | 10 |
| abstract_inverted_index.teratogenicity | 53 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 96 |
| corresponding_author_ids | https://openalex.org/A5101527594 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 13 |
| corresponding_institution_ids | https://openalex.org/I180670191 |
| citation_normalized_percentile.value | 0.99418001 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |